JATT II Acquisition Corp

JATT II Acquisition Corp(JATT)股票分析

$10.340

+0.091 (+0.88%)收盤時

Loading chart…
最高
10.340
開盤
10.275
成交量加權均價
10.32
成交量
658.00
市值
—
最低
10.275
成交金額
6.79K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

JATT II Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target, and the Company has not engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. The Company is not engaged in any business operations and has not generated any revenue.

AI 分析 of JATT II Acquisition Corp (JATT)

持有

Currently, Zura Bio Ltd (JATT) is not a strong buy due to its low price performance and negative earnings. The stock is trading at $10.25, which is only 1.9% above its 52-week low of $9.99. Additionally, the RSI is at 35.681, indicating that the stock is approaching oversold territory but is not yet a clear buy signal. The forward P/E ratio is 0, showing no expected earnings growth, which raises concerns about its profitability.

估值指標

JATT II Acquisition Corp(JATT)目前預期本益比為 0.00,5 年平均預期本益比為 。

預期本益比

5 年均值 P/E
目前P/E
0.00

預期 EV/EBITDA

5 年均值 EV/EBITDA
目前EV/EBITDA
0.00

預期股價營收比

5 年均值 P/S
目前P/S
0.00

持有 JATT 的大戶

C

Commodore Capital LP

+ 持有JATT

+40.77%

3個月報酬率

事件時間軸

2026-08-21 (ET)

10:00:00

Jatt II Acquisition Corp Trading Halted Due to Volatility

2026-06-29 (ET)

10:00:00

JATT II Acquisition Corp Ordinary Shares Trading Halted

07:30:00

Talawar Tx and JATT II to Merge, Expected to Raise $285 Million

2026-04-20 (ET)

11:30:00

AEVEX Opens Above $20 in IPO Debut

資訊

JATT 常見問題 —— 由 Alphio AI 解答

JATT II Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target, and the Company has not engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. The Company is not engaged in any business operations and has not generated any revenue. It operates in the Financials sector.

Currently, Zura Bio Ltd (JATT) is not a strong buy due to its low price performance and negative earnings. The stock is trading at $10.25, which is only 1.9% above its 52-week low of $9.99. Additionally, the RSI is at 35.681, indicating that the stock is approaching oversold territory but is not yet a clear buy signal. The forward P/E ratio is 0, showing no expected earnings growth, which raises concerns about its profitability.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易